TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06642558

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline solution)
Description: 0.5 mL per dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline solution)
Description: 0.5 mL per dose
Study: NCT05498038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants are asked to complete at least 20 minutes of aerobic exercise every day, excluding clinic visits.
Study: NCT06386224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered pain self-management (CBT Condition)
Description: Participants will login to the website for 15-20 minutes per week, and complete 5 modules focused on different skills delivered over 8 weeks (e.g., symptom identification, changing negative thoughts, activity pacing)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education Program
Description: Participants will login to the website for 15-20 minutes per week, and complete 5 modules focusing on pancreatitis pain topics, including: an introduction to pancreatitis, treatment options, specific therapies, surgical procedures.
Study: NCT06028776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MS Ballroom Fitness
Description: A personalized dance-based concept focusing on balance, walking capacity, and well-being.
Study: NCT06285526

Intervention type: PROCEDURE
Intervention: Cytoreduction surgery with Hyperthermic Intraperitoneal Chemotherapy
Description: Cytoreduction surgery with Hyperthermic Intraperitoneal Chemotherapy

Intervention type: PROCEDURE
Intervention: Cephalic DuodenoPancreatectomy
Description: Cephalic DuodenoPancreatectomy
Study: NCT05144997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: ALK-positive NSCL treatment
Study: NCT05287685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screen media adapted School Readiness Parenting Program
Description: For the screen time adapted parenting intervention, screen time intervention components will be infused into the SRPP (described below) to address three primary areas shown in research to play an important role in healthy screen media use: (1) reducing and managing screen time use; (2) maximizing benefits of screen time content; and (3) promoting positive parent-child interactions during co-use of screen media. Psychoeducation and practice of these strategies will be incorporated into sessions of the SRPP in which relevant behavioral concepts are addressed.The screen time adapted parenting intervention will utilize the same format (large group, 8 weekly 1.5 hour sessions) as the SRPP.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: School Readiness Parenting Program
Description: The SRPP is an 8-week parenting program for parents of preschool aged children with externalizing behavior problems. The SRPP targets child externalizing behavior problems specifically, as well as to help parents promote children's school readiness skills. The SRPP follows a group Parent-Child Interaction Therapy (PCIT) model and also uses motivational interviewing and modelling problem solving approaches. The SRPP utilizes a large group format (10-15 parents) with weekly sessions lasting 1.5 hours. The SRPP curriculum contains traditional aspects of behavioral management strategies (e.g., improving parenting skills and the parent-child relationship; discipline strategies such as time out). Specific sessions of the SRPP also directly target parental interactions during children's learning activities and setting up homework and household structure and routines. In its original form, SRPP does not address children's screen time.
Study: NCT05349773

Intervention type: PROCEDURE
Intervention: Pneumatic tourniquet, endoscopic left radial artery harvesting
Description: Endoscopic radial artery harvesting technique is performed after applying a tourniquet over the distal arm proximally to the elbow. The tourniquet pressure is increased 90 mmHg over the systolic pressure and the tourniquet time will be monitored.~he changes in Heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be assessed before and after deflating the tourniquet every 5 minutes for 30 minutes.
Study: NCT05084378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine Lavage Solution
Description: 0.35% povidone-iodine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.35% povidone-iodine and sterile isotonic saline solution may also be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine Lavage Solution
Description: 0.35% povidone-iodine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.35% povidone-iodine and sterile isotonic saline solution may also be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Lavage Solution
Description: 0.05% chlorhexidine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.05% chlorhexidine and sterile isotonic saline may also be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Lavage Solution
Description: 0.05% chlorhexidine solution mixed with 1 litre of sterile isotonic saline solution. Commercially available products with 0.05% chlorhexidine and sterile isotonic saline may also be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Antibiotic
Description: 2 grams Vancomycin powder
Study: NCT06288217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuraStasis Stimulator System (Non-Invasive Trigeminal and Vagus Nerve Stimulation)
Description: Pulsed electrical stimulation of the trigeminal and vagus nerves paired with upper limb rehabilitation movements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Limb Rehabilitation
Description: Rehabilitation movements to improve upper limb function after stroke

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Upper Limb Rehabilitation
Description: Rehabilitation movements to improve upper limb function after stroke

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Control sham stimulation of the trigeminal and vagus nerves is delivered at the start of each session. Performed alongside standard-of-care rehabilitation.
Study: NCT05348616

Intervention type: OTHER
Intervention: epidemiology
Description: To review of medical records to describe diagnosis and severity of the disease.

Intervention type: OTHER
Intervention: epidemiology
Description: To review of medical records to describe diagnosis and severity of the disease.

Intervention type: OTHER
Intervention: epidemiology
Description: To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.

Intervention type: OTHER
Intervention: epidemiology
Description: To compare pre- and per-Covid-19 epidemics in terms of numbers of admissions, and proportion of severe disease.
Study: NCT05084378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Antibiotic
Description: 2 grams Vancomycin powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Antibiotic
Description: 2 grams Vancomycin powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Lavage Solution
Description: 1 litre of sterile isotonic saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Lavage Solution
Description: 1 litre of sterile isotonic saline
Study: NCT05274035

Intervention type: DRUG
Intervention: Perampanel
Description: For children ≥4 years old, the initial dose is 2 mg per day, the titration interval is ≥2 weeks, the daily dose is increased by 2 mg each time (based on clinical response and tolerability), and the maintenance dose is ≥4 mg per day, up to a maximum dose of 12 mg per day.~For children \<4 years old, the initial dose is 0.04 mg/kg per day, the titration interval is ≥ 2 weeks, the daily dose is increased by 0.04 mg/kg each time (based on clinical response and tolerability), and the maintenance dose is ≥ 0.08 mg/day per day kg, the highest dose is 0.24 mg/kg per day.~According to the actual clinical situation, the initial dose and addition plan are judged by the investigator.
Study: NCT06036108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712FUM/ Brexpiprazole fumarate
Description: In Period 1, a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered at least 10 hours of fasting. In Period 2, following at least 10 hours of fasting, the subject will consume a high-fat meal within 20 minutes, after which a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered within 10 minutes of finishing the meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712FUM/ Brexpiprazole fumarate
Description: In Period 1, following at least 10 hours of fasting, the subject will consume a high-fat meal within 20 minutes, after which a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered within 10 minutes of finishing the meal. In Period 2, a single oral dose of two 24 mg tablets of brexpiprazole QW formulation (48 mg as brexpiprazole) will be administered following at least 10 hours of fasting.
Study: NCT05645120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: All participants attended to a two-part nutrition education program. The education intervention program was administered in two sessions, one week apart. Before the intervention, a pre-test was administered to determine the knowledge and beliefs attitudes of participants. After the pre-test each session consisted of a PowerPoint presentation of about 20 minutes. Education topics included components of adequate-balanced nutrition and its relationship with COVID-19, introduction of food groups, the association between COVID-19 and dietary supplements, herbal foods in the prevention/treatment of COVID-19, considerations regarding DS/HF, food-drug interactions, and COVID-19 drugs and food interactions. The presentation was concluded with the nutritional recommendations for COVID-19. The post-tests were shared with the participants at the end of the second session of the education intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: All participants attended to a two-part nutrition education program. The education intervention program was administered in two sessions, one week apart. Before the intervention, a pre-test was administered to determine the knowledge and beliefs attitudes of participants. After the pre-test each session consisted of a PowerPoint presentation of about 20 minutes. Education topics included components of adequate-balanced nutrition and its relationship with COVID-19, introduction of food groups, the association between COVID-19 and dietary supplements, herbal foods in the prevention/treatment of COVID-19, considerations regarding DS/HF, food-drug interactions, and COVID-19 drugs and food interactions. The presentation was concluded with the nutritional recommendations for COVID-19. The post-tests were shared with the participants at the end of the second session of the education intervention.
Study: NCT04744467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Mono- or bilateral implantation of toric intraocular lenses PODEYE TORIC. If only one eye qualifies for toric lens implantation due to small amount of pre-existing corneal astigmatism, one eye will be implanted with PODEYE TORIC and the contralateral eye will be receive an implantation with the monofocal parent lens PODEYE (PhysIOL sa/nv, Liège, Belgium).
Study: NCT05710588

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor-motor dual-task training
Description: The intervention compromises balance-related tasks which are selected among the tasks often used in balance rehabilitation and motor secondary tasks might be required hand dexterity like popping a fidget toy or reaching ability like touching wall. All sessions will be individual. The initial training session will be undertaken in University of Plymouth. This will be followed by a recorded training video programme which can be accessible through Panopto- a University-led, web-based platform- undertaken in the participants' home for 30 minute sessions, three times a week over 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor-cognitive dual-task training
Description: The intervention compromises (1) balance-related tasks which are selected among the tasks often used in balance rehabilitation and (2) cognitive secondary tasks might required to activate sensory and cognitive systems like listening podcast and memorizing the details about it or reading a tongue twister and repeating. intervention delivery will be the same with M-DTT group.
Study: NCT06359015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral Metformin schedule:~Day 1: 500 milligrams in morning Day 2: 500 milligrams two times a day Day 3: 1000 milligrams in morning, 500 milligrams in evening Day 4 onwards: 1000 milligrams two times a day based on individual tolerance~Oral Esomeprazole schedule:~40 milligrams Oral Esomeprazole daily until delivery which can be tapered down to 20 milligrams daily based on individual tolerance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 40 milligrams Oral Esomeprazole daily until delivery which can be tapered down to 20 milligrams daily based on individual tolerance.
Study: NCT06013163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenical® vs EMP 22
Description: Each participant will first use Xenical® TID for 9 days and then EMP22TID for 9 days (in total 27 doses of each drug).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMP 22 vs Xenical®
Description: Each participant will first use EMP22 TID for 9 days and then Xenical® TID for 9 days (in total 27 doses of each drug).
Study: NCT06430268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant decontamination with titanium curette
Description: Titanium curettes (Hu-Friedy, Chicago, Illinois, USA) will be used for supra and submucosal around the implant, with and without flap elevation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant decontamination with titanium curette
Description: Titanium curettes (Hu-Friedy, Chicago, Illinois, USA) will be used for supra and submucosal around the implant, with and without flap elevation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implant decontamination with Air-Flow device
Description: Air-polishing (Airflow Prophylaxis Master, EMS, Nyon, Switzerland) will be carried out with AIR-FLOW powder PLUS (EMS) containing erythritol (sugar alcohol, 14 μm), amorphous silica and 0.3% chlorhexidine to decontaminate implants with and without flap elevation. The device will be adjusted to a power setting of 5 bar static pressure and a maximum level of irrigation with water.
Study: NCT05770622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First-dose trough dose adjustment calculator - using early TDM (first-dose trough) to determine an early dose adjustment if the predicted steady-state trough is outside of target range (10-20mg/L)
Description: CALCULATOR: A 'First-dose trough dose adjustment calculator' was developed based on a population pharmacokinetic model. A participant's post-menstrual age, weight, creatinine, target trough concentration, dose, dosing interval and first-dose trough concentration (taken immediately before the second dose is due) are entered into the calculator. The calculator determines if a dose adjustment is required (based on whether the predicted steady-state trough concentration is \<10mg/L or \>20mg/L) and, if required, recommends a new adjusted dose.
Study: NCT05068830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ExPlas
Description: ExPlas (plasma from fit donors) is a Investigational Medicinal Product. ExPlas is plasma drawn by plasmapheresis once a month for 4 months, from a total of 30 donors (aged 18-40, BMI ≤27 kg/m2 and VO2max \>50 mL/kg/min) at the Blood Bank at St. Olavs Hospital. All unites will be virus inactivated by the Intercept method (Cerus corporation, US) in accordance with the procedures at Blood Bank at St. Olavs Hospital.~The transfusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octaplasma
Description: Octaplasma is defined as a Investigational Medicinal Product. Octaplasma is human pooled plasma produced by Octapharma (Lachen, Switzerland). The transfusion volume will be 200 mL at every time point .~The main study consists of 6 rounds of examinations in addition to 12 plasma transfusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is provided by the hospital pharmacies in Central Norway. The infusion volume will be 200 mL at every time point.~The main study consists of 6 rounds of examinations in addition to 12 saline infusions during the time span of one year (weekly transfusions in 3 four-week periods) and one round of examinations 2 years after baseline. A follow-up visit is also planned 5 years after baseline.
Study: NCT05261490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maplirpacept (PF-07901801)
Description: PF-07901801 Escalation (3-dose-level 12, 24, and 48 mg/kg), in combination with Pegylated Liposomal Doxorubicin (40mg/m2) will be administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maplirpacept (PF-07901801)
Description: PF-07901801 Escalation (3-dose-level 12, 24, and 48 mg/kg), in combination with Pegylated Liposomal Doxorubicin (40mg/m2) will be administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Description: RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in combination with pegylated liposomal doxorubicin 40mg/m2
Study: NCT04856865

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose ADP101
Description: Active powder formulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose ADP101
Description: Active powder formulation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pooled Placebo
Description: Placebo powder
Study: NCT05261490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Description: RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in combination with pegylated liposomal doxorubicin 40mg/m2
Study: NCT05908656

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Investigational procedure
Description: Subjects that consent will have a single blood draw either via a finger stick or via venous blood draw (blood will be placed on a 5 spot blood card) used to determine whether they have Gaucher Disease or ASMD
Study: NCT06430268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implant decontamination with Air-Flow device
Description: Air-polishing (Airflow Prophylaxis Master, EMS, Nyon, Switzerland) will be carried out with AIR-FLOW powder PLUS (EMS) containing erythritol (sugar alcohol, 14 μm), amorphous silica and 0.3% chlorhexidine to decontaminate implants with and without flap elevation. The device will be adjusted to a power setting of 5 bar static pressure and a maximum level of irrigation with water.
Study: NCT04394559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discharge Order Sets
Description: Discharge order sets will be implemented in the electronic health record and will provide surgeons a guideline for a recommended dose and duration of opioids for each commonly performed orthopedic surgery.
Study: NCT05084300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education
Description: A total of 10 PNE sessions (Neuroscience pain education) will be carried out, two each week in addition medical treatment similar to control group (Usual care). The NPE sessions will be conducted by an experienced NPE certified physical therapist in 35 minute face-to-face group sessions. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: The control group (Usual care) is treated with usual treatment, managment or medication for fibromyalgia, anxiolytics, antidepressants, analgesics. Depending on the medical needs and criteria of patients´s primary care physician.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: The control group (Usual care) is treated with usual treatment, managment or medication for fibromyalgia, anxiolytics, antidepressants, analgesics. Depending on the medical needs and criteria of patients´s primary care physician.
Study: NCT05762393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm-p80 + GLA-SE
Description: Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm-p80 + GLA-SE
Description: Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm-p80 + GLA-SE
Description: Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.
Study: NCT06208124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM-6-415
Description: Twice daily, oral tablet administered in 21-day cycles until treatment discontinuation criteria are met.
Study: NCT05843175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and meal testing (acute stimuli)
Description: Pre-meal exercise: 1º milkshake intake + 2º exercise test~Post-meal exercise: 1º exercise test + 2º milkshake intake~Non-exercise meal: Only milkshake intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and meal testing (acute stimuli)
Description: Pre-meal exercise: 1º milkshake intake + 2º exercise test~Post-meal exercise: 1º exercise test + 2º milkshake intake~Non-exercise meal: Only milkshake intake